Clinical Outcomes
Cross-source consensus on Clinical Outcomes from 1 sources and 5 claims.
1 sources · 5 claims
Other
Other
Highlighted claims
- The primary endpoint is steroid-free clinical and endoscopic remission at week 8. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)
- Primary remission requires stool frequency subscore ≤1, rectal bleeding subscore 0, and endoscopic subscore ≤1. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)
- The trial plans 38 patients per arm, with possible expansion to 100 patients for dropouts. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)
- Sustained remission is assessed at week 52 using adapted Mayo criteria and absence of rescue therapy. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)
- Secondary clinical outcomes include Partial Mayo, SCCAI, and IBD-Control across multiple follow-up weeks. — Transfer of faeces in ulcerative colitis 2: improving efficacy – study protocol for a multicentre randomised controlled trial (TURN2 study)